
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
GB Sciences, Inc. announced it has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to assess the company's intellectual property portfolio and help with pre-IND planning for its cannabis-based formulations. Pre-IND consulting services will be performed by Michael F. Murphy, MD, PhD, chief medical and scientific officer (CMSO) of Worldwide Clinical Trials, Inc.
Read the full release






